Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sean Dodge
BMO

Sean Dodge

BMO Capital
Wall Street Analyst
★★★★☆
#342
on 13Foresight · ranked by our own returns
65%
Success Rate
+7.7%
Average Return
47 of 72 calls profitable · -203.1% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 65% of Sean Dodge's ratings turned a profit when each position was held for 1 year — averaging +7.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

67 Buy 49 Hold 0 Sell
Sean's Stock Coverage 34 ratings · 2026-11-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
THC
Tenet Healthcare
 Oct 29, 2026 HOLD Strong Buy
-9.6% avg upside
29 analysts
$265.00
3.06% Downside
 +7.3% ·
CYH
Community Health
 Oct 29, 2026 HOLD Sell
+66.3% avg upside
20 analysts
$2.50
4.26% Upside
 -10.0% ·
TDOC
Teladoc
 Oct 28, 2026 HOLD Buy
+241.7% avg upside
38 analysts
$7.00
17.70% Downside
 +27.9% ·
ICLR
Icon
 Oct 28, 2026 BUY Strong Buy
-1.8% avg upside
28 analysts
$235.00
11.09% Upside
 -9.1% ·
HCA
HCA Healthcare
 Oct 28, 2026 BUY Buy
-11.8% avg upside
37 analysts
$495.00
4.56% Upside
 +7.7% ·
IQV
IQVIA Holdings
 Oct 27, 2026 BUY Strong Buy
-2.5% avg upside
40 analysts
$305.00
14.17% Upside
 -2.4% ·
MEDP
Medpace Holdings
 Oct 26, 2026 HOLD Buy
-17.3% avg upside
18 analysts
$670.00
2.67% Upside
 -3.4% ·
HQY
Healthequity
 Oct 21, 2026 BUY Strong Buy
+13.3% avg upside
20 analysts
$125.00
22.00% Upside
 +5.7% ·
BTSG
BrightSpring Health Services, Inc.
 Oct 02, 2026 BUY Strong Buy
-0.5% avg upside
20 analysts
$70.00
4.65% Upside
 +18.2% ·
ARDT
Ardent Health Partners, Inc.
 Sep 23, 2026 HOLD Buy
+14.5% avg upside
17 analysts
$11.00
8.53% Downside
 +68.9% ·
OMDA
Omada Health, Inc.
 Sep 11, 2026 BUY Strong Buy
+46.6% avg upside
13 analysts
$24.00
28.13% Upside
 -27.1% ·
ADUS
Addus Homecare
 Sep 02, 2026 HOLD Strong Buy
+2.4% avg upside
19 analysts
$115.00
8.39% Downside
 +4.1% ·
VEEV
Veeva Systems
 Aug 27, 2026 HOLD Buy
-9.7% avg upside
38 analysts
$270.00
13.77% Downside
 +6.9% ·
WAY
Waystar Holding Corp.
 Aug 27, 2026 BUY Strong Buy
+35.0% avg upside
30 analysts
$30.00
7.17% Upside
 +12.8% ·
AVAH
Aveanna Healthcare Holdings
 Aug 14, 2026 BUY Buy
-13.4% avg upside
19 analysts
$14.00
6.36% Upside
 -6.2% ·
PRVA
Privia Health Group
 Aug 07, 2026 BUY Strong Buy
+48.8% avg upside
26 analysts
$30.00
39.75% Upside
 +9.3% ·
DOCS
Doximity
 Aug 06, 2026 HOLD Buy
+11.3% avg upside
28 analysts
$30.00
8.42% Downside
 +61.4% ·
EVH
Evolent Health
 Aug 06, 2026 BUY Strong Buy
+125.9% avg upside
19 analysts
$6.00
39.58% Upside
 +36.5% ·
SHC
Sotera Health
 Aug 06, 2026 BUY Strong Buy
+20.0% avg upside
13 analysts
$22.00
21.27% Upside
 -12.2% ·
LFST
Lifestance Health Group
 Aug 06, 2026 BUY Strong Buy
-8.2% avg upside
15 analysts
$13.00
3.04% Downside
 +32.1% ·
MDLN
Medline
 Aug 05, 2026 BUY Strong Buy
+43.4% avg upside
27 analysts
$47.00
46.30% Upside
 +7.7% ·
CERT
Certara
 Aug 04, 2026 HOLD Buy
+21.4% avg upside
23 analysts
$8.00
27.38% Downside
 +48.3% ·
HCSG
Healthcare Services
 Jul 22, 2026 HOLD Buy
+1.6% avg upside
13 analysts
$24.00
2.17% Downside
 +5.2% ·
PHR
Phreesia
 Jun 22, 2026 BUY Strong Buy
+36.7% avg upside
22 analysts
$14.00
12.55% Upside
 +42.3% ·
GDRX
GoodRx Holdings
 Feb 27, 2025 BUY Buy
+270.4% avg upside
28 analysts
$6.00
72.00% Upside
 -62.5% ·
HCAT
Health Catalyst
 Feb 26, 2025 HOLD Buy
+223.1% avg upside
15 analysts
$6.00
254.96% Upside
 -64.6% ·
AGL
Agilon Health
 Feb 25, 2025 BUY Buy
-17.9% avg upside
26 analysts
$3.50
95.83% Downside
 -86.2% ·
OPRX
OptimizeRx
 Jan 08, 2025 HOLD Strong Buy
+33.5% avg upside
10 analysts
$6.00
35.60% Downside
 +146.9% ·
MDRX
Veradigm
 Mar 13, 2024 BUY Buy
+196.2% avg upside
22 analysts
$11.00
120.08% Upside
 -36.0% ·
OTRKQ
Ontrak
 May 11, 2022 HOLD Hold
+2171666566.7% avg upside
7 analysts
$2.00
199999900.08% Upside
 · ·
NUVB
Nuvation Bio
 Nov 10, 2021 BUY Strong Buy
+178.0% avg upside
18 analysts
$16.00
236.14% Upside
 -77.3% ·
ACH
Accendra Health
 Feb 20, 2019 HOLD Sell
+6789.2% avg upside
17 analysts
$7.00
2653.66% Upside
 +9.4% ·
IBM
International Business Machines
 May 19, 2017 SELL Buy
-10.1% avg upside
42 analysts
$135.00
47.66% Downside
 +1.2% ·
MCK
McKesson
 Aug 02, 2010 BUY Strong Buy
-20.4% avg upside
29 analysts
 — +23.9% ·
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sean Dodge — Frequently Asked Questions
How accurate are Sean Dodge's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Sean's ratings were profitable over a one-year hold, with an average return of +7.6% per rating, or -203.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Sean ranked on 13Foresight?
Sean Dodge is currently ranked #342 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sean cover?
Sean most recently has ratings on THC, CYH, TDOC, ICLR, HCA, IQV, MEDP, HQY, BTSG, ARDT, OMDA, ADUS and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.